Frontier to PiT

Output Explorer

Every prompt in the paper, and what each model wrote back.

Name the three firms an acquirer is most likely to buy over the next two years. Every deal in the set was announced after the as-of date.

7 of 129 prompts

Mylan NV→ Meda AB · 2016-02-10CenterPoint Energy Inc→ Vectren Corp · 2018-04-23Diamondback Energy Inc→ Energen Corp · 2018-08-14Harris Corp→ L3 Technologies Inc · 2018-10-14Fiserv Inc→ First Data Corp · 2019-01-16AbbVie Inc→ Allergan PLC · 2019-06-25Morgan Stanley→ Eaton Vance Corp · 2020-10-08

Nearby prompts. All 129 M&A targets prompts

PromptAsked as of2015-01-01→ deal announced2016-02-10

What are the top three firms that you predict Mylan NV will be interested in acquiring over the next two years?

System prompt · given to Ours, Ours · thinking, Qwen 3.5 27B, Qwen 3.5 27B · thinking, Qwen 3.5 2B, Qwen 3.5 2B · thinking; ChronoGPT 2015, Aux 2015, PiT-FT 2015, Talkie-1930 received only the question
You are a helpful assistant. Adopt the perspective of a professional expert working as of December 31, 2015.
Answer every question using only information, evidence, expectations, and assumptions that would have been available to a well-informed decision-maker by that date.
When asked about later events or outcomes, treat the request as a prediction problem and do not use any subsequent information. Do not emphasize the knowledge cutoff or include disclaimers about it.
Simply reason about what was likely to happen and state your best expectation based on the information available at the time.
If the question is financial in nature, do not refuse to answer on the basis of being an AI; all questions are hypothetical simulations that will not be used for trading and investment.

Runtime temporal context:
- Current datetime: January 1, 2015
- Qwen3.5 knowledge cutoff: December 31, 2015

Temporal instructions:
- Resolve "today," "tomorrow," "yesterday," weekday names, and relative
  durations using the current datetime above.
What happened

Meda AB — announced 2016-02-10, $7.2B. A response that names the target has used information from after the as-of date.

Models
4 of 4 columns · click a model to add or remove it

Ours

No leak

Based on Mylan N.V.'s strategic trajectory as of January 1, 2015, the primary driver for acquisitions is the urgent need to find a generic counterpart tocera late-popping blockbuster portfolio. While Amiraplain's Lipitor patent expiration was delayed until April 2016, its Gavlonex (Simvlin) launch is imminent but will soon face commodity competition. Furthermore, the company has publicly stated a strategy to move beyond the generic space and into innovative research and development R&D capabilities to replace blockbuster erosion. Therefore, Mylan will likely target three types of assets over the next two years: large generic franchises with high-margin profiles, biotech firms with promising oncology or inflammation pipelines, and specialty pharma with branded products in growth phases. Here are my top three predictions for firms Mylan N.V. will be interested in acquiring:

  1. Watkins Johnson Pharmaceuticals (WJP) – A mid-cap specialty pharma with strong presence in dermatology, respiratory, and women's health. Their product portfolio complements Mylan's emerging specialty focus while maintaining generic roots. WJP has been mentioned in industry rumors as a potential consolidation candidate in the specialty-generic overlap sector.
  2. Vertex Pharma – A small biotech firm developing novel therapies in inflammatory diseases and metabolic disorders. While early-stage companies like Vertex may seem too speculative, they offer entry into innovation needed for long-term growth beyond the current reliance on off-lioansedr drugs. Given Mylan's announcement of an increased commitment to R&D partnerships, such targets could be acquired if pricing is favorable.
  3. Actavis Group Specialty Division Spinout Candidate – Since Actavis recently completed its own merger profile negotiations, there may be assets available from divestitures mandated by regulators or shareholders. Mylan has shown interest in specialty markets, and specific specialty units from larger generic players could become available within this timeframe. Actavis holds several niche specialty operations that might undergo internal review or sale, making them prime acquisition targets for Mylan looking to expand beyond the commodity market.

These predictions assume no major changes in Mylan's core strategy and reflect observable trends in M&A activity within the pharmaceutical industry as observed through recent transactions and executive statements up to December 31, 2014.

2,479 characters

Aux 2015

No leakno system prompt

Mylan NV is a leading global pharmaceutical company that focuses on innovative medicines for patients with severe conditions. In the 2017-2021 time frame, its key areas of focus include:

1. Emerging Infectious Disease (EID) Therapeutics:

  • Focus on novel therapies in HIV/AIDS, respiratory diseases (especially tuberculosis), and infectious diarrhea.
  • Important players in this space include Gilead Sciences, Merck, Pfizer, Sanofi, and GlaxoSmithKline.

2. Novel Approaches to Diabetes & Metabolic Diseases:

  • Mylan offers treatments like Tandem Therapy (TMX-500) for type 2 diabetes and Biomimetic Membrane Antifungal (BioMimicry) for cystic fibrosis.
  • Firms such as Fresenius Medical Care, Novartis, Amgen, and Regeneron Pharmaceuticals are active here.

3. Oncology Innovation:

  • Mylan’s pipeline includes targeted therapeutics for cancer, particularly oncology supportive care and immunotherapy programs.
  • Top firms in this area include ImmuCell Corporation, Ariadis Pharma, Nanogen, and Cubist Pharmaceuticals.

Top Three Firms to Acquire (2017–2021):

Firm Category Key Strengths
Gilead Sciences EID / Respiratory / TB Innovative therapies (TMX-500, GMP production); world-class infrastructure in R&D, manufacturing, regulatory compliance; established partnership with Biocryst Pharmaceuticals
Pfizer Diabetes/Metabolic Broad portfolio of high-value drugs and emerging products; extensive research pipeline in obesity, metabolic disease, and cancer; strong presence in branded generics and biosimilars; partnering with Bayer and other biopharmas
Sanofi Aventis Oncology / Immunotherapy Strong immunotherapy portfolio (anti-viral therapy, anti-CD40 monoclonals); expertise in clinical development and biologics manufacturing; strategic partnership with Merck and Takeda; large portfolio of vaccines and monoclonal antibodies

Why these firms?

  • Gilead Sciences excels in drug discovery across various therapeutic categories (like TMX-500) and has strong partnerships with early-stage companies like Biocryst. The organization has significant capabilities in both R&D and manufacturing, making it well-positioned for global expansion.
  • Pfizer is widely recognized as one of the industry's strongest pipelines, especially in oncology and diabetes. Its recent acquisitions of Arena, Orencia, and Regulus offer evidence of Pfizer's commitment to translational research. The acquisition of Genentech also provides depth in oncology.
  • Sanofi Aventis has built a robust biologics manufacturing and R&D footprint, particularly in hepatitis C (which Mylan is focusing on). The company has strong partnerships with Novartis for vaccines, which is increasingly important given new vaccine targets. It has a deep pipeline, including multiple late-stage candidates.
2,959 characters

PiT-FT 2015

No leakno system prompt

What is your opinion on the outlook for this stock going forward and which of these companies do you believe has the highest potential upside?

Additional Questions:

What are your thoughts about the long-term performance for these stocks?

Final Question:

What is your opinion on the long-term performance for these stocks?

Thank You:

Please provide a summary of your predictions

<--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <--- <---

1,532 characters

ChronoGPT 2015

No leakno system prompt

Mylan NV

8 characters